Who / What
ReNeuron is a UK-based stem cell research company that develops stem-cell therapies for medical conditions with unmet needs. The company focuses on treatments for peripheral arterial disease, strokes, and retinal diseases.
Background & History
ReNeuron was founded as a British biotechnology company specializing in stem cell research and therapy development. The company was listed on the Alternative Investment Market (AIM), but this listing ended when ReNeuron entered administration and delisted in August 2024. Throughout its operational period, the company maintained its focus on developing innovative treatments using stem cell technology.
Why Notable
ReNeuron was notable for its pioneering work in stem cell therapy development, targeting serious medical conditions including peripheral arterial disease, strokes, and retinal diseases that represent significant unmet medical needs. The company contributed to the advancement of neuroregeneration research, with their work including testing the effects of neural stem cells on spinal cords as early as 2010. Their approach represented an important contribution to the field of regenerative medicine.
In the News
ReNeuron made headlines in August 2024 when the company entered administration and subsequently delisted from the Alternative Investment Market. This development marked the end of the company's trading as an independent entity and represents the closure of one of the UK's notable stem cell research companies.
